Market cap of just ₹109 Cr, current price at ₹69, and a stock that has already delivered 74.6% return in 6 months and 46.3% in one year. Not bad for a company that, on TTM basis, still shows PAT of ₹-3.07 Cr and EPS of ₹-1.94.
Welcome to the rollercoaster called Jeevan Scientific Technology Ltd.
Latest quarterly numbers (Dec 2025) show:
Revenue up 52.4% YoY
PAT up a mind-bending 1,191% YoY
Quarterly EPS at ₹0.90
OPM at 27.43%
But zoom out and you see:
ROCE just 2.8%
ROE a microscopic 0.28%
Debt at ₹24.93 Cr
Promoter holding down to 30.25%
So what’s happening here? A genuine turnaround? Or a quarter that accidentally did cardio?
Let’s dissect this clinical research lab like auditors on caffeine.
2. Introduction – CRO With Drama, Audits and Warrants
Incorporated in 1999, Jeevan Scientific is not a pharma manufacturer. It’s the behind-the-scenes guy — the Contract Research Organization (CRO) that runs clinical trials, bioequivalence studies, and pharmacovigilance.
Basically, pharma companies make drugs. Jeevan tests them on humans. Politely.
The company runs a 20,000 sq. ft. clinical research center with 132 beds across four units, capable of conducting 150–200 studies annually. It also has:
10 LC-MS/MS systems
ELISA reader
NABL-accredited pathology lab
So infrastructure? Present.
Regulatory audits?
USFDA – 8
WHO – 2
UKMHRA – 1
CDSCO – 5
NABL – 3
That’s 19 regulatory audits closed.
But here’s the twist.
Despite that impressive compliance list, the company’s financials over the last 3 years have looked like a patient in ICU:
3-year sales growth: -11.6%
3-year profit variation: -75.3%
ROE (3-year): -2.87%
So the question is: Is Q3 FY26 the revival episode? Or just a seasonal miracle?
Let’s go deeper.
3. Business Model – WTF Do They Even Do?
Imagine you’re a pharma company wanting to sell a generic drug in the US.
You can’t just say: “Trust me bro, it works.”
You need:
Bioavailability (BA) studies
Bioequivalence (BE) trials
PK/PD studies
Regulatory documentation
Data management
Audit compliance
Enter Jeevan Scientific.
Services include:
Clinical Trial Services
Early & late phase trials
Post-marketing surveillance
Real-world evidence
Trials for complex generics & biosimilars
BA/BE Services
Food effect studies
Age/gender studies
SAD & MAD studies
Statistical analysis using SAS, Win Nonlin, CDISC
Pharmacovigilance
Database management
Regulatory audit support
Literature search
Revenue split FY24:
Domestic: 74%
Exports: 26%
So largely India-focused with some global exposure.
And then comes the spicy update: They set up Nayas Laboratories Pvt Ltd, a subsidiary focused on advanced drug delivery tech and patentable biomedical polymers.
Also: Board approved investment of ₹120 Crores in Naya Pharma.
Wait. The entire market cap is ₹109 Cr. And they approved ₹120 Cr investment?
